Home Press Release Syphilis Testing Market Size Projected to Reach $1509.15 million by 2034 | 11.76%

Syphilis Testing Market Size Projected to Reach $1509.15 million by 2034 | 11.76%

23 Jul, 2026

According to Straits Research the global syphilis testing market size is estimated at $556.70 million in 2025 and is projected to reach $1509.15 million by 2034, growing at a CAGR of 11.76% from 2026-2034.

The global syphilis diagnostics market is witnessing remarkable growth, driven by the increasing adoption of integrated syphilis testing pathways that combine rapid point-of-care screening with laboratory-based confirmatory testing in a single diagnostic workflow. This approach enables faster and more accurate diagnosis, improves treatment initiation, and supports effective disease surveillance. Additionally, the rising prevalence of sexually transmitted infections (STIs), growing awareness of early detection, expanding government screening programs, and continuous advancements in diagnostic technologies are further accelerating the growth of the global syphilis diagnostics market.

Market Dynamics

The syphilis testing market is supported by a strong driver in the form of rising participation in community-based screening campaigns that expand routine access to diagnostic services across urban and semi-urban regions. These campaigns increase test uptake among individuals who may not visit clinical facilities regularly, resulting in higher overall use of rapid kits and laboratory assays. A restraint affecting the market is the limited completion of follow-up evaluations after initial screening, as a portion of individuals do not return for confirmatory testing due to scheduling barriers or low awareness of next steps, which reduces the total number of fully assessed cases. An opportunity emerges from the expansion of small community centers dedicated to year-round syphilis awareness and routine walk-in testing, creating consistent access points for screening and strengthening the reach of diagnostic services across diverse neighborhoods.

North America dominated the global syphilis diagnostics market in 2025, accounting for a 42.23% market share. The region's leadership is driven by the expansion of syphilis screening programs across hospitals, community health centers, and public health outreach initiatives. Increased testing volumes have been supported by broader community-based screening campaigns, routine STI assessments, and antenatal syphilis testing programs aimed at improving early diagnosis and treatment. The growing adoption of point-of-care diagnostic solutions, advancements in laboratory automation, and enhanced access to community healthcare facilities have further strengthened market growth. Additionally, the introduction of innovative diagnostic assays, including rapid screening tests, confirmatory laboratory diagnostics, and dual HIV-syphilis testing formats, has accelerated adoption across both public and private healthcare settings, reinforcing North America's dominant position in the global syphilis diagnostics market.

Market Highlights

  • Type: Based on Type, the Primary syphilis segment is anticipated to register the fastest CAGR of 12.12%.
  • Test Type: Based on Test Type, Treponemal immunoassays (TPPA, TPHA) segment dominated the market growth with a revenue share of 35.63% in 2025.
  • Technology: Based on Technology, the Immunoassay segment dominated the market growth in 2025 with a revenue share of 45.64%.
  • Location of Testing: Based on Location of Testing, point-of-care testing segment is anticipated to register the fastest CAGR of 12.67%.
  • Regional Insights: North America held a dominant share of the global market, accounting for 42.23% share in 2025.

Market Segments

  1. By Type (2026-2034)
    1. Primary Syphilis
    2. Secondary Syphilis
  2. By Test Type (2026-2034)
    1. Non-treponemal tests (RPR, VDRL)
    2. Treponemal immunoassays (TPPA, TPHA)
    3. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
    4. Rapid diagnostic tests (lateral flow immunoassays)
    5. Molecular tests (PCR/NAAT)
    6. Multiplex STI panels including syphilis targets
  3. By Technology(2026-2034)
    1. Molecular Diagnostics
    2. Immunoassay
    3. Others
  4. By Location of Testing(2026-2034)
    1. Laboratory Testing
      1. Commercial/Private Labs
      2. Public Health Labs
    2. Point of Care Testing